ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

John M. Wrangle, Vamsidhar Velcheti, Manish R. Patel, Elizabeth Garrett-Mayer, Elizabeth G. Hill, James G. Ravenel, Jeffrey S. Miller, Mohammad Farhad, Kate Anderton, Kathryn Lindsey, Michele Taffaro-Neskey, Carol Sherman, Samantha Suriano, Marzena Swiderska-Syn, Amy Sion, Joni Harris, Andie R. Edwards, Julie A. Rytlewski, Catherine M. Sanders, Erik C. YuskoMark D. Robinson, Carsten Krieg, William L. Redmond, Jack O. Egan, Peter R. Rhode, Emily K. Jeng, Amy D. Rock, Hing C. Wong, Mark P. Rubinstein

Research output: Contribution to journal › Article › peer-review

286 Scopus citations

Fingerprint

Dive into the research topics of 'ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial'. Together they form a unique fingerprint.

Medicine & Life Sciences